London-based health tech startup uMed has raised £9.8 million in a new funding round that is aimed directly at combatting staggering NHS statistics that have seen patient access to industry clinical trials nearly fall off a cliff. The company reports that in addition to ramping up UK-focused efforts, a portion of the funding will be used to expand its presence in North America.
uMed’s £9.8 million investment was provided via Delin Ventures, AlbionVC, Playfair Capital and Silicon Valley’s 11.2 Capital.
The uMed platform is a clinical research tool that enables healthcare institutions to participate in programmes that target specific patient groups for research and population health activities by taking on the workload of identifying, screening and engaging their patients on their behalf.
Leveraging health record data to target specific patient groups, uMed then automates communication with patients, including the collection of patient-reported outcomes. In so much, this lifts the admin burden from healthcare institutions and facilitates their participation in a range of programmes including clinical trial recruitment, registries and population health initiatives.
“We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research,” comments uMed founder and CEO Dr. Matt Wilson. “Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients.”